<DOC>
	<DOCNO>NCT00665067</DOCNO>
	<brief_summary>Researchers use abnormal blood and/or bone marrow cell , material derive abnormal cell , like DNA , RNA , protein plasma , laboratory study . Toenail clipping provide normal material like DNA comparison abnormal material derive blood and/or bone marrow . The result study correlate subject ' disease symptom response experimental treatment . The MPD-RC researcher interested study molecule blood bone marrow , exact molecule change time investigator choose promising investigation . The investigator attempt good understand cause MPD develop improve method diagnosis treatment disease . These syndrome carry high risk develop leukemia . It important continue learn blood cancer learn effectiveness potential side effect various treatment . It believe basic knowledge cancer cell well effect treatment lead improvement current therapy development entirely new treatment disease . The MPD-RC hoping determine number laboratory test ( biomarkers ) allow prediction response future patient treatment would receive .</brief_summary>
	<brief_title>Correlative Biomarker Study Patients With Myeloproliferative Disorders</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Patients register study meet eligibility criteria one MPDRC treatment protocol link study . Patients diagnose follow Myeloproliferative disorder include : polycythemia vera ( PV ) , idiopathic myelofibrosis ( IM ) , essential thrombocythemia ( ET ) participate treatment protocol MPDRC eligible . Patients must sign informed consent participate Myeloproliferative Disorders Research Consortium ( MPDRC ) treatment study protocol companion study . The subject must also sign consent participate mandatory companion study . See inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Myeloproliferative Disease</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Idiopathic Myelofibrosis</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Philadelphia Chromosome Negative</keyword>
	<keyword>Clonal Hematopoietic malignancy</keyword>
</DOC>